Swissmedic publishes Information concerning an official Warning from Brazil regarding Falsified Medicinal Product
Recommendation
Tuesday, 29 September 2026 14.00 - 16.00 h
GDP-compliant Transport Processes: from Risk Assessment to Practical Implementation
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
The Swissmedic has been informed by the Brazilian Health Regulatory Agency ANVISA that Brazil has suspended all imports of medicinal products from three Turkish wholesalers. The reason for this is the export of falsified units from Turkey to Brazil. One of the batches was also obtained from Turkey and sold to Brazil by a Swiss wholesaler.
In this regard, an information for Swiss companies was published. The Swissmedic points out that Swiss companies are also not permitted to supply medications obtained from the Turkish wholesalers to Brazil.
The names of the three wholesalers and further information can be found on the website of Swissmedic.
Related GMP News
10.09.2026European GDP Association Developments May through August 2026
10.09.2026Reminder: Submit your Presentation Proposal for the GDP Forum 2027 by 30 September
10.09.2026GDP in the US: FDA Launches DSCSA Assessment for Small Dispensers and Issues Exemptions
11.08.2026GDP for APIs: APIC Publishes Updated "How to Do" Document
11.08.2026Where to Find Information on UK Wholesale Authorisations